ConclusionFluorescein-guided SLNB is a viable option for detection of lymph node metastases in clinically node negative patients with early breast cancer. It achieves a high pooled Sentinel Lymph Node Identification Rate (SLN-IR) of 93% with a false negative rate of 5.6% for the detection of axillary lymph node metastasis. (Source: Breast Cancer Research...

ConclusionsBreast MRI has the potential to improve the diagnosis of BI-RADS 4A microcalcifications on mammography. We propose a potential clinical pathway that patients with BI-RADS 4A on mammography who are premenopausal, have no personal history of breast cancer (family history) or have non-clustered distribution of calcifications can undergo MRI...

ConclusionThis prospective study using preoperative ICG perfusion mapping demonstrated safety, feasibility, and good prognostic outcomes.Level of evidenceIII. (Source: Breast Cancer Research and Treatment)

ConclusionTrials to investigate who can safely and effectively be treated with shorter durations of anti-HER2 therapy are needed. This study provides important insights to patients ’ perspectives on shorter durations of anti-HER2 treatment, and their concerns regarding potential increased cancer risk with less treatment. (Source: Breast Cancer Research...

ConclusionLow ALNM rate (4.1%) suggests that routine SLNB for patients with MIBC is unnecessary but  can be valuable for patients with specific risk factors. Ongoing trials for omitting SLNB in early breast cancer, and further subanalyses focusing on rare populations with MIBC are necessary. (Source: Breast Cancer Research and Treatment)

ConclusionsIn our cohort, HER2-low TNBC patients exhibits specific clinical characteristics and response features to NAC. (Source: Breast Cancer Research and Treatment)